Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 83,680

Document Document Title
WO/2023/150361A1
Kava and kratom compositions are described herein along with the methods of producing the same. The description contained herein describes methods for making a purified kava composition that is free or substantially free of flavokavain A...  
WO/2023/150635A1
The present disclosure provides methods for treating hematological malignancies using menin inhibitors in combination with P-gp inhibitors and/or BCRP inhibitors. Compositions for use in these methods are also provided.  
WO/2023/149450A1
The combination of a cytotoxic anticancer agent and/or a molecularly targeted drug, and a MALT1 inhibiting agent that is a compound represented by formula (I) indicated in the specification, or a salt thereof, or a co-crystal, a hydrate,...  
WO/2023/148401A1
The invention relates to the treatment of neurodegenerative diseases such as Parkinson patients with motor complications in need of Continuous Dopaminergic Stimulation. According to the invention a kit of pharmaceutical preparations is p...  
WO/2023/147790A1
Disclosed in the present invention are a brain glioma biomarker MLKL gene and a use thereof. MLKL expression is remarkably high in brain glioma; the high-expression MLKL gene and protein are related to poor prognosis of glioma; reducing ...  
WO/2023/149420A1
The present disclosure relates to a method for preventing or treating myopia and a composition to be used in this method. The present inventors found that VEGF deficiency induces loss of the choroidal capillary plate and choroidal thinni...  
WO/2023/150237A1
This disclosure provides methods of treating cystic fibrosis or a CFTR-mediated disease comprising administering Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. The disclosure a...  
WO/2023/150093A1
A method of treating post-COVID condition(s) in a patient in need thereof includes administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.  
WO/2023/150085A1
Platelet-derived extracellular vesicles that include mitochondria (PEVs) are used in the treatment of an ocular disorder, or a symptom of the ocular disorder. The PEVs are collected by obtaining blood from one or more donors, adding an a...  
WO/2023/149656A1
The present invention relates to dual stimuli-sensitive drug-releasing extracellular vesicles for chemo-sonodynamic therapy and, more specifically, to extracellular vesicles sensitive to both ultrasounds and pH, with a sonosensitizer, an...  
WO/2023/143425A1
The present application relates to a method for improving cognitive disorders. The method comprises administering a regulator that regulates an intron retention shearing product DIR and/or a functional fragment thereof of a DNA damage-in...  
WO/2023/147134A2
The present disclosure relates generally to a method of treating post-traumatic stress disorder, schizophrenia, acute stress disorder, anxiety, depression, or bone loss comprising administration of a neurokinin (NK) receptor antagonist t...  
WO/2023/146291A1
Disclosed is a pharmaceutical composition for preventing or treating a mental disorder. More specifically, disclosed is a pharmaceutical composition for treating or preventing a mental disorder, including substance-related and addictive ...  
WO/2023/147552A1
Compositions and methods of improving radiation therapy are provided. The composition typically includes an effective amount of 7-DHC or a derivative or analog thereof. The methods typically include administering the composition to a sub...  
WO/2023/145735A1
Provided is a new therapy/prevention for aging-related disorders including sarcopenia. The present invention pertains to a pharmaceutical composition that contains an expectorant (examples thereof include compounds, or pharmaceutically a...  
WO/2023/147135A1
The present disclosure relates generally to a method of treating prostate cancer or delaying progression of prostate cancer comprising administration of a neurokinin (NK) receptor antagonist to a patient.  
WO/2023/142318A1
Disclosed is a pharmaceutical composition for treating viral hepatitis, the pharmaceutical composition comprising a non-steroidal anti-inflammatory drug and an mTOR inhibitor. The pharmaceutical composition is used for treating or preven...  
WO/2023/142996A1
A method for preventing, alleviating and/or treating a disease or disorder associated with administering an antineoplastic agent. The method comprises administering to a subject in need thereof a NO-NSAID compound or a pharmaceutically a...  
WO/2023/142978A1
The present disclosure provides use of CDK16 as a target in the preparation of a medicine for treating triple-negative breast cancer (TNBC). According to the present disclosure, research has found that the knock-down of the CDK16 can sig...  
WO/2023/142357A1
Disclosed are a drug/siRNA co-delivery nanocomplex, a method for preparing same, and use thereof. The nanocomplex comprises: a nanocore carrying a drug, a cationic polymer coating the nanocore, and siRNA. The nanocomplex may be PD@RPPT/s...  
WO/2023/145884A1
Provided are: a polynucleotide that includes (i) a base sequence according to any of SEQ ID NOS: 1-3, (ii) a base sequence in which one to three bases have been deleted, substituted, inserted, or added in a base sequence according to any...  
WO/2023/143358A1
The present application relates to a pharmaceutical composition, a microneedle formulation, a microneedle drug delivery system, a preparation method and use. The pharmaceutical composition comprises the following components in parts by w...  
WO/2023/145530A1
This therapeutic agent for cancer contains a compound that acts on a retinoid receptor and a BRAF inhibitor. The therapeutic agent for cancer is for use alongside a BRAF inhibitor, and contains a compound that acts on a retinoid receptor...  
WO/2023/142456A1
Disclosed are a retinoic acid-modified LYTAC molecule, a method for preparing same, and use thereof. The retinoic acid-modified LYTAC molecule has a structure as shown in formula (I). In formula (I), n represents the molecular weight of ...  
WO/2023/145869A1
Provided are a method for producing a composition for a formulation and a method for producing a formulation that prevent degradation of a drug during production and can readily provide a formulation with excellent granulation properties...  
WO/2023/144626A1
Provided herein is a combination of pharmaceutical compositions for co-administration, including (i) a pharmaceutical composition comprising a phthalazinone derivative and (ii) a pharmaceutical composition comprising at least one antican...  
WO/2023/145844A1
Provided is a substance demonstrating an anti-tumor effect by introducing changes in a tumor microenvironment (TME), including inhibition or suppression of TME formation. This invention relates to an anti-human CXCL1 antibody including d...  
WO/2023/142729A1
The present invention relates to the use of a ribofuranosyl pyridine derivative for the prevention or treatment of epilepsy or convulsions, which belongs to the field of medicine. The drug of the present invention can improve the convuls...  
WO/2023/146274A1
The present invention relates to a composition for preventing, alleviating and/or treating alopecia or poliosis (or poliosis circumscripta), and the like, and was accomplished by identifying that an aldehyde dehydrogenase 2 (ALDH2) activ...  
WO/2023/143261A1
A pH-responsive analgesic agent for targeting a damaged segment dorsal root ganglion and use thereof. A pH-responsive carrier is adopted to embed an opioid analgesic agent to prepare a peripheral nerve damage analgesic agent; the damaged...  
WO/2023/142317A1
A pharmaceutical composition for treating viral hepatitis, the use thereof in the treatment or prevention of viral hepatitis, and the use thereof in the preparation of a drug for treating or preventing viral hepatitis, especially hepatit...  
WO/2023/143474A1
Disclosed herein are methods for treating a subject having or suspected of having gastric cancer, and a therapeutic compound effective to regulate one or more genes, wherein the one or more genes are directly or indirectly regulated by a...  
WO/2023/144832A1
The present invention relates to a dry powder inhalation formulation of endothelin receptor antagonists, angiotensin II receptor antagonists and combinations thereof for the treatment of pulmonary arterial hypertension. The dry powder in...  
WO/2023/143221A1
A composition for preventing or treating osteoporosis, a preparation thereof, and use thereof in preventing or treating osteoporosis. The composition is mainly composed of a GPX4 agonist and a lipoxygenase 15(Alox-15) inhibitor, and coop...  
WO/2023/143608A1
Disclosed is a composition, comprising an epigenetic drug and a glutamine metabolism regulator. The composition enables metabolic and epigenetic reprogramming in a tumor microenvironment, activates an immune response of a body to a tumor...  
WO/2023/144332A1
There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer and/or the treatment or prevention of a viral infection, wherein A1, A2, L1 and R1 have meanings as prov...  
WO/2023/145871A1
Provided are: a production method for a formulation composition from which it is possible to easily obtain a formulation that has a high hardness and excellent granulation properties while inhibiting degradation of a drug during producti...  
WO/2023/143308A1
The present invention relates to a bifunctional molecule formed by fusion of a PD1 antibody and interleukin 2. The bifunctional molecule comprises a heterodimer composed of a first monomer and a second monomer as follows: (1) a first mon...  
WO/2022/265878A9
A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing or eliminat...  
WO/2023/138696A1
The present invention relates to a drug and method for nucleoside (acid) drug therapy of limiting chronic hepatitis B, in particular to the use of an HBV virus entry inhibitor and an optional immunomodulator in the preparation of a drug ...  
WO/2023/140350A1
The present invention provides a pharmaceutical composition for suppressing organ fibrosis, characterized by having an angiotensin II receptor antagonist as an active ingredient, and being administered at a dosage of 0.2 times or less th...  
WO/2023/139506A1
This invention provides method of treating hypertension in a hypertensive subject, the method comprising administering to the subject a CYP 11β2 beta hydroxylase inhibitor once or twiceper day in an amount sufficient to inhibit 50% or m...  
WO/2023/140329A1
A medicine for treating or preventing cancer, the medicine comprising a first active ingredient used together with a second active ingredient, the first active ingredient being a compound expressed by formula (1) or a salt thereof or a s...  
WO/2023/140385A1
A pharmaceutical composition for treating or preventing at least one disease selected from the group consisting of inflammatory bowel disease and intestinal tumor, said pharmaceutical composition comprising an inhibitor for the binding o...  
WO/2023/141087A1
The present invention relates to combination therapy with (a) a mutant IDH inhibitor, or a pharmaceutically acceptable salt thereof, (b) a deoxyadenosine analog, or a pharmaceutically acceptable salt thereof, (c) a platinum agent, and (d...  
WO/2023/137941A1
A nucleic acid aptamer and a use thereof. The nucleic acid aptamer is a nucleic acid aptamer that can specifically recognize bladder tumor cells and can internalize into the bladder tumor cells. The nucleic acid aptamer has good specific...  
WO/2023/137659A1
A series of polymers having the properties of acid-sensitive degradation and temperature sensitivity and a drug loading composition thereof. A polymer has a structure represented by formula (1) and has the properties of degradation and t...  
WO/2023/139381A1
An inhalable formulation comprising at least one amino acid and at least one beta-2-agonist is disclosed. The inhalable formulation may be administered by pressurized metered dose inhaler.  
WO/2023/140309A1
[Problem] To elucidate the mechanism of an anti-tumor effect of a ketogenic diet therapy to discover a novel cancer treatment method. [Solution] Provided is a composition for treating cancer, the composition comprising a ketogenic diet t...  
WO/2023/138593A1
Provided in the present invention are an antibacterial stent having a micro-nano double-layer structure, and a preparation method therefor and the use thereof, which belong to the technical field of oral medical products. The method for ...  

Matches 651 - 700 out of 83,680